BackSeneca Biopharma Overview

Seneca Biopharma Total Revenue

Seneca Biopharma's total revenue is $21K, below the Healthcare sector average of $110B.

Get informed when a big investor buys or sells

+ Follow

Quarterly Revenue

$13520.00
440.8% YoY

As of Dec 2020

Annual Revenue (TTM)

$21020.00
91.92% YoY

Trailing 12 months ending Dec 2020

Average Revenue (Comparison Companies)

Loading

Total Revenue History

Loading

Total Revenue Comparison

Loading

Annual Revenue Growth Rate (%)

Loading

Annual Revenue Growth (Absolute)

Loading

Seneca Biopharma (SNCA) FAQ

The latest total revenue for SNCA is $21K as of December 2020. That compares with $260K in the prior-year period — down 91.9% year over year. That is below the Healthcare sector average of $110B. Investors often review this figure alongside Seneca Biopharma's historical trend and sector peers before judging valuation or financial health.

Over the past year, SNCA's total revenue moved from $260K to $21K — a 91.9% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Seneca Biopharma's operating scale or balance-sheet position.

Against Healthcare companies, SNCA currently prints $21K for total revenue, while the sector average sits near $110B. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Seneca Biopharma's growth, margins, and balance sheet.

A total revenue figure of $21K for SNCA is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $110B. Explore the charts below for those layers of context.

After noting SNCA's total revenue ($21K), review year-over-year change from $260K, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.